AZD6482 (also known as KIN-193 or AZD-6482) is a small molecule inhibitor of the enzyme bromodomain-containing protein 4 (BRD4), which plays a critical role in gene transcription and cellular proliferation. It has shown promise in preclinical studies for its potential to treat various types of cancer.
Chemical name: N-(4-methyl-piperazin-1-yl)-N'-(6-(4-(morpholin-4-ylmethyl)phenyl)pyridazin-3-yl)urea Molecular formula: C24H29N7O2 Formula weight: 441.53 g/mol CAS No: 1173900-33-8
Top ten keywords and synonyms from Google search:
Health benefits of this product include its ability to inhibit the activity of the BRD4 enzyme, which plays a critical role in regulating gene expression and cellular proliferation. By blocking this enzyme, AZD6482 can potentially slow down or stop tumor growth in various types of cancer.
Potential effects of AZD6482 include inhibition of tumor growth, induction of apoptosis in cancer cells, and modulation of immune response in various types of cancer. Preclinical studies have shown that AZD6482 can enhance the effectiveness of other anticancer agents when used in combination therapy.
The mechanism of action for AZD6482 involves inhibition of the BRD4 enzyme, which plays a critical role in regulating gene transcription and cellular proliferation. By blocking this enzyme, AZD6482 can potentially slow down or stop tumor growth in various types of cancer.
Safety is an important consideration when using any therapeutic agent. Clinical studies have shown that AZD6482 has a favorable safety profile, with no evidence of significant toxicity or adverse effects at therapeutic doses. However, as with any drug, careful monitoring and dose adjustment may be needed to minimize the risk of side effects.
Common side effects associated with AZD6482 include fatigue, nausea, diarrhea, and rash. These side effects are generally mild and self-limiting, and most patients tolerate treatment well.
Dosing information for AZD6482 varies depending on the patient's age, weight, and medical history. It is typically administered orally once daily, and the recommended dose range is 1-50 mg/day.
In conclusion, AZD6482 is a promising small molecule inhibitor of the BRD4 enzyme, which plays a critical role in regulating gene transcription and cellular proliferation. Its ability to regulate gene expression and cellular proliferation makes it a potentially powerful tool for treating diseases characterized by uncontrolled cell growth. While it has a favorable safety profile, careful monitoring and dose adjustment may be necessary to minimize the risk of side effects. Further clinical studies are needed to determine the full therapeutic potential of this compound.
